At the conference this month, editor-in-chief Jonah Comstock caught up with Scot Ebbinghaus, vice president of clinical research at Merck, who spoke a bit about Keytruda’s anniversary ...

The company's head of clinical research, Scot Ebbinghaus, said Merck will "continue to advance our clinical development programme to evaluate Keytruda-based combinations and novel candidates for ...

We sat down with Dr. Scot Ebbinghaus, a medical oncologist and vice president of clinical development at Merck, to learn where research currently stands. Neoantigens are unique proteins that ...